Case Study: A flexible solution for launching a new molecule in oncology

The approach

• Seamless entry into Canadian market 

  Acted as importer through Innomar DEL to support submission to Health Canada. 

• Comprehensive market access plan 

  Optimized the payer strategy and supported reimbursement of oral oncolytic in a timely manner.  

• Continual support and service 

  Provided extensive capability to support challenges within the oncology landscape, providing a range of potential approaches. Our support and range of services also helped to keep the commercialization journey moving steadily. 

The outcome

By leveraging our QA and importation services, the client completed Health Canada submissions, which was a critical step in the journey into this new market. Through the support and services of our integrated commercialization team, a seamless plan was created to effectively transition SAP patients to a commercial drug post-NOC by leveraging our Market Access expertise. Although the client opted to outsource the molecule with another manufacturer, they were able to strengthen and improve their negotiation position through the commercialization steps that were taken throughout our process.

Key insight

Clients can begin the commercialization journey early and adapt services as the oncology space requires and as strategic decisions are made.

At a glance

• Extensive expertise in Canadian oncology landscape and market access
• Understanding of market access implications of an oral product
• Strong relationships to support market access with public and private payers
• A flexible suite of services to support wide range of regional payer and Cancer Centre needs